Bayer (ETR: BAYN) Q1 beat lifts shares as Supreme Court Roundup ruling looms

Bayer AG (ETR: BAYN) climbed 3.70% to €38.35 on Xetra on Tuesday morning after the Leverkusen-based life science conglomerate reported first-quarter 2026 results that beat consensus by close to 19% on core earnings per share, with an unexpected boost from Crop Science licensing income offsetting continued pressure on its pharmaceuticals division. The move comes against a falling DAX, down almost a percent on Strait of Hormuz tensions, and arrives just weeks before the U.S. Supreme Court is expected to rule on the federal preemption question in Monsanto v. Durnell, the case Bayer has framed as the single largest catalyst for closing out its 17 billion dollar Roundup litigation exposure. With shares still well below the 52-week high of €49.78 and litigation cash outflows of roughly €5 billion guided for the year, retail investors face one of the clearest binary catalyst windows of any DAX name in 2026.

What does Bayer AG do and why has the share price spent two years trapped between pipeline progress and Roundup litigation?

Bayer AG is a German life science conglomerate operating in three roughly equal-weighted divisions: Crop Science, which makes seeds, herbicides and crop protection products and accounted for around 47% of 2025 sales; Pharmaceuticals, which produces prescription drugs across cardiology, oncology, ophthalmology and women’s health and accounted for roughly 38% of sales; and Consumer Health, the over-the-counter brands business including Aspirin, Bepanthen and Berocca, which contributed around 13%. The company employs roughly 88,000 people and operates across more than 80 countries, with the United States and Europe its two largest geographies by revenue.

The strategic and financial bind that has weighed on the share price since 2018 traces almost entirely to a single decision. Bayer paid $63 billion in that year to acquire Monsanto, the American agrochemical giant, and inherited tens of thousands of lawsuits alleging that the glyphosate-based weedkiller Roundup caused non-Hodgkin lymphoma in users. Despite the U.S. Environmental Protection Agency consistently maintaining that glyphosate is not carcinogenic, juries in state courts have repeatedly found against the company, and Bayer has so far paid out more than €15 billion in Roundup-related settlements and verdicts. Roughly 4,500 cases remain pending in the federal multi-district litigation, with thousands more in state courts.

Layered on top of the litigation overhang is a pharmaceuticals patent cliff. Xarelto, the blood-thinner that historically anchored the division’s earnings, has rolled off patent protection across major markets, with 2026 expected to be the final year in which the expiry materially drags reported results. Eylea, the ophthalmology blockbuster commercialised in partnership with Regeneron, faces biosimilar competition outside the U.S. The combination has left Bayer needing to bridge a multi-year revenue gap with newer launches while servicing a debt pile of more than €32 billion that limits strategic optionality. CEO Bill Anderson, in post since June 2023, is attempting to engineer the turnaround through a radical reorganisation he calls Dynamic Shared Ownership.

How strong were Bayer’s Q1 2026 results and which divisions drove the earnings beat?

The Tuesday morning release showed group sales of €13.405 billion, a 4.1% increase on a currency- and portfolio-adjusted basis, with reported revenue absorbing an €886 million negative currency headwind. EBITDA before special items rose 9.0% to €4.453 billion, comfortably ahead of the prior-year period despite a €321 million foreign exchange drag. Core earnings per share reached €2.71, up 12.9% year-on-year and roughly 19% above the consensus estimate of €2.28 polled by Investing.com. Net income improved to €2.763 billion, and the headline result was strong enough that Bayer raised its reported sales and EBITDA guidance modestly on currency translation effects, while confirming the underlying Fx-adjusted guidance unchanged.

The standout division was Crop Science, where EBITDA before special items jumped 17.9% to €3.014 billion. The headline number was flattered by approximately €450 million of soybean trait licensing revenue, but even stripping that out, organic growth in the core agrochemicals business was around 1.4%, supported by stronger seed sales in North America and lower raw material costs. Consumer Health delivered a 5% sales increase despite difficult comparisons in the U.S. and China markets, with management citing brand investment paying back on the cough, cold and allergy portfolio. Pharmaceuticals was the soft spot, with sales roughly flat year-on-year on a currency-adjusted basis and EBITDA before special items down around 7.5%, hit by the Xarelto patent expiry, biosimilar pressure on Eylea, and increased launch investment behind newer drugs.

The free cash flow line tells the harder underlying story. Bayer reported negative free cash flow of €2.32 billion for the quarter, primarily reflecting €2 billion of legal settlement payouts in respect of glyphosate and PCB litigation. Net financial debt closed the quarter at €32.5 billion. With approximately €5 billion of litigation-related cash outflows guided for the full year, free cash flow will remain a constraint on dividend recovery and balance sheet repair, and the company has held its 2025 dividend at the legal minimum of €0.11 per share for a second year running, a payment made in late April 2026.

What is the Supreme Court Roundup ruling and why does Monsanto v. Durnell matter for the BAYN share price?

The single most important catalyst for Bayer in the next two months is the U.S. Supreme Court ruling in Monsanto v. Durnell, with oral arguments having been heard on April 27, 2026 and a decision expected by the end of June. The case concerns John Durnell, a plaintiff who alleged that his non-Hodgkin lymphoma was caused by Roundup exposure. The legal question at stake is whether state-law failure-to-warn claims against pesticide manufacturers are preempted by the federal Federal Insecticide, Fungicide, and Rodenticide Act, given that the EPA has approved Roundup labels without a cancer warning. A ruling in Bayer’s favour would, in the company’s own framing, “largely end” the Roundup litigation by eliminating the principal legal theory plaintiffs use to win jury verdicts.

The political backdrop has tilted in Bayer’s direction. The Trump administration filed a brief supporting Bayer’s preemption argument in late 2025 and sought oral argument time on the company’s behalf, with the Solicitor General agreeing with Monsanto that FIFRA preempts state failure-to-warn claims. President Trump signed an executive order in February 2026 invoking the Defense Production Act to safeguard domestic glyphosate production, characterising the chemical as critical to national defence and granting limited legal immunity to manufacturers complying with federal directives. Reports from the April 27 oral arguments described the bench as divided, with some justices receptive to the preemption argument and others skeptical of overriding state tort law, leaving the outcome genuinely uncertain.

A second moving piece is the $7.25 billion class settlement Bayer has proposed to resolve current and future Roundup non-Hodgkin lymphoma claims, which received preliminary approval from a Missouri judge in March 2026. The opt-out deadline for class members is June 4, 2026, just ahead of the expected Supreme Court ruling, which has created tactical complexity for plaintiff law firms. Several firms representing more than 20,000 plaintiffs have publicly objected to the settlement terms and asked for delays, arguing the deal was assembled without sufficient input. For Bayer shareholders, the bull scenario is a favourable SCOTUS ruling combined with broad class settlement acceptance, which would convert a multi-billion-euro contingent liability into a defined and largely funded outflow. The bear scenario is an adverse ruling that reopens the entire state-court litigation pipeline.

How is Bayer rebuilding its pharmaceutical division around Nubeqa, Kerendia, Asundexian and Beyonttra ahead of 2027?

The pharmaceutical division’s near-term earnings pressure obscures what the company has framed as an emerging multi-year growth phase from 2027. At its Pharma Media Day in Berlin in early April 2026, Bayer reaffirmed its target of returning the pharma division to mid-single-digit percentage growth from 2027 and lifting the divisional operating margin toward 30% by 2030, with margin expansion expected to begin from 2028 onward. The bridge is a portfolio of five core launches: anticoagulant Asundexian, prostate cancer treatment Nubeqa, kidney disease drug Kerendia, cardiovascular treatment Beyonttra, and menopausal symptom drug Lynkuet.

Asundexian is positioned as the strategic successor to Xarelto. The drug is a first-in-class Factor XIa inhibitor that delivered positive results in the Phase III OCEANIC-STROKE study, demonstrating a 26% reduction in stroke after non-cardioembolic ischemic stroke or high-risk transient ischemic attack, with no increase in major bleeding versus placebo. Bayer has pegged peak sales potential at more than €5 billion. Nubeqa and Kerendia each carry €3 billion peak sales projections set at recent J.P. Morgan healthcare conferences, with Kerendia having received expanded FDA and Japanese regulatory approvals for heart failure with left ventricular ejection fraction at or above 40%. The combined peak sales potential of the five-drug growth cohort exceeds €12 billion, more than offsetting the €4 to €5 billion in eroded Xarelto and Eylea revenue.

Two recent newsflow items reinforce the pipeline trajectory. On May 6, 2026, Bayer announced the acquisition of San Francisco-based Perfuse Therapeutics for $300 million upfront plus up to $2.15 billion in milestones, a total deal value of approximately $2.45 billion. The acquisition brings full rights to PER-001, a small molecule endothelin receptor antagonist delivered via an intravitreal implant, currently in Phase 2 development for glaucoma and diabetic retinopathy. The strategic logic is that PER-001 complements Bayer’s existing Eylea franchise as biosimilar competition pressures the older product, and Phase 2b/3 trials are scheduled to begin in the second half of 2026. On May 7, Bayer reported that the Phase III REVEAL study of investigational PET/CT radiotracer I-124 evuzamitide met its primary endpoints for sensitivity and specificity in diagnosing cardiac amyloidosis, opening a potential diagnostic franchise in a fast-growing therapeutic area.

Why is Crop Science both the immediate bright spot and the longest-term overhang for Bayer shareholders?

Crop Science is in the unusual position of being simultaneously the division that drove the Q1 2026 earnings beat and the source of the unresolved Roundup legal liability. The 17.9% EBITDA growth in the quarter was supported by a soybean trait licensing payment of around €450 million that does not recur every quarter, but underlying business momentum was also genuine. North American soybean and corn seed volumes held up well, raw material costs continued to ease from the 2022 to 2023 highs, and the division benefited from a more favourable mix in fungicides and non-glyphosate herbicides. Glyphosate-based product sales remained pressured, both by historical volume normalisation and by ongoing brand sensitivity in markets where the litigation narrative has dominated headlines.

The structural Crop Science thesis turns on three factors. First, the litigation outcome. A favourable Supreme Court ruling would not just close out the financial liability but also remove the strategic ceiling on growing the glyphosate franchise in the U.S. market. Second, the regulatory backdrop. The Trump executive order classifying glyphosate as critical to national defence has effectively underwritten the product’s continued U.S. availability, and the proposed five-year U.S. farm bill working through Congress includes provisions that would limit manufacturer liability where products are compliant with EPA labelling. Third, the competitive landscape. Biological crop protection products from BASF, Syngenta and a wave of mid-cap challengers represent a longer-term threat to the chemical herbicide model, although adoption curves remain early.

The capital allocation question raised on German retail forums is whether Bayer should spin off Crop Science to unlock value separately from the pharmaceutical and consumer health businesses. CEO Bill Anderson has so far resisted full separation, arguing that the conglomerate structure provides cash flow support during the litigation workout and that no separation can occur until the Roundup liability is bounded. Resolution of the SCOTUS case may finally make the separation conversation actionable. Citi, JPMorgan and Barclays analysts have all flagged a Crop Science spin or carve-out as a meaningful potential value-unlock if and when the legal overhang clears.

What does the macro environment in 2026 mean for German chemicals and agriculture stocks?

The macro backdrop for the broader German chemicals sector remains challenging, which is part of why Bayer’s relative outperformance against the DAX on Tuesday is meaningful. The Ifo institute warned in early April that the ongoing Iran conflict and the Strait of Hormuz disruption have deepened the crisis in Germany’s chemical industry, with higher energy costs, supply chain pressure on helium and other critical inputs, and weaker industrial demand combining to compress margins. The federal government has responded with a Chemieagenda package of support measures, but the structural competitiveness gap with U.S. and Chinese producers has widened.

For Bayer specifically, the macro picture cuts in three directions. The euro has weakened against the dollar through the first quarter of 2026, which translated into the €886 million revenue headwind in Q1 but provides operating leverage in U.S. dollar revenue translation going forward. Pharmaceutical pricing pressure in the U.S. remains a watchpoint, with both Medicare drug pricing negotiations and the broader political conversation around drug costs influencing forward earnings. Agricultural commodity prices, particularly soybean and corn, have been volatile around the Latin American planting cycle and U.S. growing season, which directly affects farmer purchasing behaviour for seeds and crop protection inputs.

The forward currency translation effect is the reason management raised the reported 2026 guidance on a euro basis while confirming the underlying Fx-adjusted guidance. Bayer now expects 2026 sales in a range of €44.5 to €46.5 billion and EBITDA before special items of €9.4 to €9.9 billion, with adjusted earnings per share guided to €4.30 to €4.80. If the company hits the upper end of that range and the SCOTUS ruling lands favourably, the path to a sub-€30 billion net debt position by the end of 2027 becomes credible.

How is the analyst community and the German retail forum scene positioned on Bayer ahead of the SCOTUS ruling?

The sell-side consensus on Bayer has tilted constructive through 2026, with 14 Buy ratings and zero Sell calls polled by Investing.com, an average twelve-month price target of €48.47, a high of €60 and a low of €25. UBS reaffirmed its Buy on May 8 following the REVEAL readout and the Perfuse deal, and Barclays maintained Buy on May 6. The wide range of price targets is itself an unusual indicator of how binary the SCOTUS-dependent valuation has become, with the bear case implying continued litigation pain and the bull case implying a re-rating toward Morningstar’s quantitative fair value estimate of €71.72. Implied upside from the May 12 close to consensus sits at roughly 27%.

The wallstreet-online.de forum sentiment is described as neutral, with the user community focused on three debates. The first is the divergence between consistently positive news flow on the pipeline, including the Asundexian Phase III readout, the Perfuse acquisition, and the early signs of glyphosate regulatory progress, and a share price that has only this week broken decisively above €38. The second is the SCOTUS opt-out timeline, with retail investors actively tracking the June 4 settlement opt-out deadline and the SCOTUS ruling expectation by end of June, with price target conversations clustering at €40 to €45 in a base case and above €50 in a positive ruling case. The third is the long-running speculation around a Monsanto carve-out or Crop Science separation, which surfaces in forum discussion every time the litigation news flow turns supportive.

The dividend remains a sore point for income-focused retail shareholders. Bayer paid only €0.11 per share for the 2025 financial year, the legal minimum, marking the second consecutive year of the floor distribution. Management has consistently framed the dividend cut as a temporary measure to support deleveraging, and analysts expect a return to a more meaningful payout once litigation cash outflows normalise from 2028 onward. For now, retail attention has shifted to the upside optionality on the share price rather than near-term income.

Bayer share price catalysts and risks for retail investors watching BAYN

• The May 12 Q1 2026 results delivered a 19% core EPS beat versus consensus, with Crop Science EBITDA up 17.9% on a soybean licensing windfall and underlying agrochemical strength, supporting the rebased 2026 reported guidance for €44.5 to €46.5 billion in sales and €9.4 to €9.9 billion EBITDA before special items.
• The U.S. Supreme Court ruling in Monsanto v. Durnell on federal preemption of state failure-to-warn claims is expected by end of June 2026, with a favourable outcome positioned by management to largely end the multi-billion-euro Roundup litigation.
• The June 4 opt-out deadline for the proposed $7.25 billion class settlement creates near-term legal and price action complexity, with class participation rates and law firm responses the key intermediate data points.
• The Pharmaceutical division is targeting a return to mid-single-digit growth from 2027 and a 30% operating margin by 2030, anchored on Asundexian, Nubeqa, Kerendia, Beyonttra and Lynkuet, with combined peak sales potential above €12 billion.
• The May 6 acquisition of Perfuse Therapeutics for up to $2.45 billion adds PER-001 to the ophthalmology pipeline, with Phase 2b/3 trials in glaucoma and diabetic retinopathy starting in the second half of 2026 and a strategic fit alongside the existing Eylea franchise.
• Sell-side consensus sits at €48.47, with UBS Buy, Barclays Buy, and Morningstar quantitative fair value at €71.72, implying meaningful upside if litigation risk resolves and pharma execution holds.
• Key risks remain an adverse Supreme Court ruling, slower-than-guided uptake of the new pharma launches, prolonged dividend suppression, foreign exchange and energy cost pressure on the German chemicals base, and the timing and shape of any eventual Crop Science separation.